(415) 353-9900 (appts)
(415) 353-9505 (academic fax), (415) 353-9994 (clinic fax)

Box 1706, UCSF; San Francisco, CA 94143-1706

additional websites:

UCSF Physician Referral Directory

Harvard University, B.A., 1982-1986, Biochemistry
State University of New York at Stony Brook, M.D., 1987-1991, Medicine

(from 1994-2006)

Scanlon KJ, Ishida H, Kashani-Sabet M. Ribozyme-mediated reversal of the multi-drug resistant phenotype. Proc Natl Acad Sci USA 91: 11123-11127, 1994.

Funato T, Jiao L, Tone T, Wang W, Kashani-Sabet M, Scanlon KJ. Suppression of H-ras mediated transformation in NIH3T3 cells by a ras ribozyme. Biochem Pharmacol 48: 1471-1475, 1994.

Ohta Y, Kijima H, Kashani-Sabet M, Scanlon KJ. Suppression of the malignant phenotype of melanoma cells by anti-oncogene ribozymes. J Invest Dermatol 106: 275-280, 1996.

Ohta Y, Kijima H, Kashani-Sabet M, Scanlon KJ. Tissue-specific expression of an anti-ras ribozyme by a retroviral vector inhibits proliferation of human malignant melanoma cells. Nucleic Acids Res 24:939-942, 1996.

Scanlon KJ, Kashani-Sabet M. Ribozymes as therapeutic agents: are we getting closer [editorial]? J Natl Cancer Inst 90: 558, 1998.

Mraz-Gernhard S, Sagebiel RW, Kashani-Sabet M, Miller JR III, Leong SPL. Prediction of sentinel lymph node micrometastasis by histologic features in primary cutaneous malignant melanoma. Arch Dermatol 134: 983-987, 1998.

Kashani-Sabet M, Sagebiel RW, Collins HE, Glassberg AB, Allen RE, Leong SPL, Small EJ. Outpatient combination chemoimmunotherapy for metastatic melanoma. Cancer 86: 2160-2165, 1999.

Yu WH, Kashani-Sabet M, Liggitt D, Moore D, Heath TD, Debs RJ. Topical gene delivery to murine skin. J Invest Dermatol 112: 370-375, 1999.

Bastian BC, Kashani-Sabet M, Hamm H, Moore DH II, Brocker EB, LeBoit PE, Pinkel D. Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin. Cancer Res 60: 1968-1973, 2000.

Suzuki T, Anderegg B, Ohkawa T, Irie A, Engebraaten O, Halks-Miller M, Holm PS, Curiel DT, Kashani-Sabet M, Scanlon KJ. Adenovirus-mediated ribozyme targeting of HER-2/neu inhibits in vivo growth of human breast cancer cells. Gene Ther 7: 241-248, 2000.

Kashani-Sabet M, Sagebiel RW, Ferreira CM, Nosrati M, Miller JR III. Vascular involvement in the prognosis of primary cutaneous melanoma. Arch Dermatol, 137:1169-1173, 2001.

Meuli M, Liu Y, Liggitt D, Kashani-Sabet M, Knauer S, Meuli-Simmen C, Harrison MR, Adzick NS, Heath TD, Debs RJ. Efficient gene expression in skin wound sites following local plasmid injection. J Invest Dermatol 116: 131-135, 2001.

Kashani-Sabet M, Yong L, Desprez PY, Liu S, Tu G, Nosrati M, Handumrongkul C, Ligget D, Thor AD, Debs RJ. Identification of gene function and functional pathways by systemic plasmid-based ribozyme targeting in adult mice. Proc Natl Acad Sci USA 99: 3878-3883, 2002.

Kashani-Sabet M, Sagebiel RW, Ferriera CMM, Nosrati M, Miller JR III. Tumor vascularity in the prognostic assessment of primary cutaneous melanoma. J Clin Oncol 20: 1826-1831, 2002.

Zettersten E, Sagebiel RW, Miller JR III, Tallapureddy S, Leong SPL, Kashani-Sabet M. Prognostic factors in patients with thick cutaneous melanoma (>4 mm). Cancer 94: 1049-1056, 2002.

Fong S, Mounkes L, Liu Y, Maibaum M, Desprez P, Thor AD, Kashani-Sabet M, Debs RJ. Functional identification of distinct sets of anti-tumor activities mediated by the FKBP gene family. Proc Natl Acad Sci USA. 100: 14253-14258, 2003.

Kashani-Sabet M, Shaikh L, Sagebiel RW, Nosrati M, Ferreira CMM, Miller JR III. NF-ƒÈB in the vascular progression of melanoma. J Clin Oncol 22: 617-623, 2004.

Nosrati M, Li S, Bagheri S, Ginzinger, D, Blackburn E, Debs RJ, Kashani-Sabet M. Antitumor activity of systemically delivered ribozymes targeting murine telomerase RNA. Clin Cancer Res. 10: 4983-4990, 2004.

You, L, He, B, Xu, Z, Uematsu, K, Mazieres, J, Naoaki, F, Mikami, I, Reguart, N, McIntosh, JK, Kashani-Sabet, M, McCormick, F, and Jablons, DM. An anti-Wnt-2 monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growth. Cancer Res. 64: 5385-5389, 2004.

Haqq C, Nosrati M, Sudilovsky D, Crothers J, Khodabakhsh D, Pulliam BL, Federman S, Allen RE, Singer MI, Leong SPL, Ljung B-M, Sagebiel RW, Kashani-Sabet M. The gene expression signatures of melanoma progression. Proc Natl Acad Sci USA. 102: 6092-6097, 2005.

Shaikh L, Sagebiel RW Ferreira CMM, Nosrati M, Miller JR III, Kashani-Sabet M. The role of microsatellites as a prognostic factor in primary malignant melanoma. Arch Dermatol. 141: 739-742, 2005.

Bagheri S, Nosrati M, Li S, Fong S, Torabian S, Rangel J, Moore DH, Federman S, LaPosa RR, Sagebiel RW, Cleaver JE, Haqq C, Debs RJ, Blackburn EH, Kashani-Sabet M. Genes and pathways downstream of telomerase in melanoma metastasis. Proc Natl Acad Sci USA. 103: 11306-11311, 2006.

Rangel J, Torabian S, Shaikh L, Nosrati M, Baehner FL, Haqq C, Leong SPL, Miller JR III, Sagebiel RW, Kashani-Sabet M. Prognostic significance of NCOA3 overexpression in primary cutaneous melanoma. J Clin Oncol. 24: 4565-4569, 2006.

Grande Sarpa H, Reinke K, Shaikh L, Leong SPL, Miller JR III, Sagebiel RW, Kashani-Sabet M. Prognostic significance of extent of ulceration in primary cutaneous melanoma. Am J Surg Pathol. 30: 1396-1400, 2006.

Selected Prior Publications

Kashani-Sabet M, Rossi JJ, Lu Y, Ma JX, Chen J, Miyachi H, Scanlon KJ. Detection of drug resistance in human tumors by in vitro enzymatic amplification. Cancer Res 48: 5775-5778, 1988.

Scanlon KJ, Kashani-Sabet M. Elevated expression of thymidylate synthase cycle genes in cisplatin-resistant human ovarian carcinoma A2780 cells. Proc Natl Acad Sci USA 85: 650-653, 1988.

Kashani-Sabet M, Wang W, Scanlon KJ. Cyclosporin A suppresses cisplatin-induced c-fos gene expression in ovarian carcinoma cells. J Biol Chem 265: 11285-11288, 1990.

Scanlon KJ, Jiao L, Funato T, Wang W, Tone T, Rossi JJ, Kashani-Sabet M. Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein. Proc Natl Acad Sci USA 88: 10591-10595, 1991.

12/7/06